Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.
Τίτλος | Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., Kalra B., Makras P., & Mantzoros C. S. |
Journal | Endocrine |
Volume | 81 |
Issue | 3 |
Pagination | 573-578 |
Date Published | 2023 Sep |
ISSN | 1559-0100 |
Λέξεις κλειδιά | Activins, Case-Control Studies, Female, Follistatin, Glycoproteins, Humans, Inhibins, Osteoporosis, Postmenopausal |
Abstract | PURPOSE: The activins-follistatins-inhibins (AFI) hormonal system is considered to regulate muscle and bone mass. We aimed to evaluate AFI in postmenopausal women with an incident hip fracture.
METHODS: In this post-hoc analysis of a hospital based case-control study, we evaluated circulating levels of the AFI system in postmenopausal women with a low-energy hip fracture admitted for fixation compared with postmenopausal women with osteoarthritis scheduled for arthroplasty.
RESULTS: Circulating levels of follistatin (p = 0.008), FSTL3 (p = 0.013), activin B and AB (both p < 0.001), as well as activin AB/follistatin and activin AB/FSTL3 ratios (p = 0.008 and p = 0.029, respectively) were higher in patients than controls in unadjusted models. Differences for activins B and AB remained after adjustment for age and BMI (p = 0.006 and p = 0.009, respectively) and for FRAX-based risk for hip fracture (p = 0.008 and p = 0.012, respectively) but were lost when 25OHD was added to the regression models.
CONCLUSIONS: Our data indicate no major changes in the AFI system in postmenopausal women at the time of hip fracture compared to postmenopausal women with osteoarthritis except for higher activin B and AB levels, whose significance, however, was lost when 25OHD was added to the adjustment models.
CLINICAL TRIALS: Clinical Trials identifier: NCT04206618.
|
DOI | 10.1007/s12020-023-03402-x |
Alternate Journal | Endocrine |
PubMed ID | 37221430 |
PubMed Central ID | 2772945 |